Moderna climbs on smaller-than-expected Q3 loss

Insulet

06/11/2025 12:06

** Shares of vaccine maker Moderna MRNA.O rise 6.4% to $25.07 premarket

** Co reports Q3 loss of 51 cents/shr vs analysts' average loss estimate of $2.11/shr - LSEG data

** Co's quarterly revenue of $1 billion beats analysts' average expectation of $886.5 million

    ** MRNA lowers the top end of its 2025 revenue forecast by $200 million on weaker-than-expected sales of its COVID-19 vaccine in the U.S

** Up to last close, stock down ~43% YTD

 (Reporting by Sahil Pandey and Christy Santhosh in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))